A randomized, double-blind phase 1 study assessing pharmacodynamic effects for ALTO-101
Latest Information Update: 13 May 2024
At a glance
Most Recent Events
- 09 May 2024 According to an Alto Neuroscience media release, company announced upcoming data presentations that highlight the companys precision psychiatry pipeline and biomarker based analyses at the Society of Biological Psychiatry (SOBP) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings, to take place May 9 to 11 in Austin, TX, and May 28 to 31 in Miami Beach, FL, respectively.
- 23 Apr 2024 Results presented in the Alto Neuroscience Media Release
- 22 Mar 2024 New trial record